Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX -- IDE ...
The Manila Times

Alpha Labs Male Enhancement Gummies Claims Evaluated: The AlphaLabs ED Gummy for Men Under Investigation

A 2026 informational overview of Alpha Labs Male Enhancement Gummies covering ingredient research context, how the brand ...
Oncology Nursing News

Alpha DaRT Trial Expansion Advances Pancreatic Cancer Study

FDA expands Alpha DaRT IMPACT trial to 40 patients, adding gemcitabine and nab-paclitaxel cohort in pancreatic cancer.
Seeking Alpha

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or ...

JERUSALEM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (DRTS) ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha ...